{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:26:57Z","timestamp":1791336417373,"version":"4.3.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,5,7]],"date-time":"2014-05-07T00:00:00Z","timestamp":1399420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00401-014-1290-2","type":"journal-article","created":{"date-parts":[[2014,5,6]],"date-time":"2014-05-06T05:52:08Z","timestamp":1399355528000},"page":"803-810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Do current therapeutic anti-A\u03b2 antibodies for Alzheimer\u2019s disease engage the target?"],"prefix":"10.1007","volume":"127","author":[{"given":"Andrew D.","family":"Watt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela A. N.","family":"Crespi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell A.","family":"Down","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Ascher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyla A.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona A.","family":"McLean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor L.","family":"Villemagne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Barnham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,5,7]]},"reference":[{"key":"1290_CR1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ (2002) The amyloid hypothesis of alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297:353\u2013356. doi: 10.1126\/science.1072994","journal-title":"Science"},{"key":"1290_CR2","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1111\/j.1471-4159.2006.03989.x","volume":"97","author":"CL Masters","year":"2006","unstructured":"Masters CL, Cappai R, Barnham KJ, Villemagne VL (2006) Molecular mechanisms for alzheimer\u2019s disease: implications for neuroimaging and therapeutics. J Neurochem 97:1700\u20131725","journal-title":"J Neurochem"},{"key":"1290_CR3","doi-asserted-by":"crossref","unstructured":"Miles LA, Crespi GAN, Doughty L, Parker MW (2013) Bapineuzumab captures the n-terminus of the alzheimer\u2019s disease amyloid-beta peptide in a helical conformation. Sci Rep 3. http:\/\/www.nature.com\/srep\/2013\/130218\/srep01302\/abs\/srep01302.html#supplementary-information","DOI":"10.1038\/srep01618"},{"key":"1290_CR4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","volume":"69","author":"K Blennow","year":"2012","unstructured":"Blennow K, Zetterberg H, Rinne JO et al (2012) Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate alzheimer disease. Arch Neurol 69:1002\u20131010. doi: 10.1001\/archneurol.2012.90","journal-title":"Arch Neurol"},{"key":"1290_CR5","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","volume":"9","author":"JO Rinne","year":"2010","unstructured":"Rinne JO, Brooks DJ, Rossor MN et al (2010) 11c-pib pet assessment of change in fibrillar amyloid-\u03b2 load in patients with alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9:363\u2013372. doi: 10.1016\/S1474-4422(10)70043-0","journal-title":"Lancet Neurol"},{"key":"1290_CR6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R, Salloway S, Brooks DJ et al (2012) Amyloid-related imaging abnormalities in patients with alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11:241\u2013249. doi: 10.1016\/s1474-4422(12)70015-7","journal-title":"Lancet Neurol"},{"key":"1290_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/eci.11.93","volume":"8","author":"BP Imbimbo","year":"2012","unstructured":"Imbimbo BP, Ottonello S, Frisardi V et al (2012) Solanezumab for the treatment of mild-to-moderate alzheimer\u2019s disease. Expert Rev Clin Immunol 8:135\u2013149. doi: 10.1586\/eci.11.93","journal-title":"Expert Rev Clin Immunol"},{"key":"1290_CR8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000112834","volume":"5","author":"P Seubert","year":"2008","unstructured":"Seubert P, Barbour R, Khan K et al (2008) Antibody capture of soluble abeta does not reduce cortical abeta amyloidosis in the pdapp mouse. Neurodegener Dis 5:65\u201371. doi: 10.1159\/000112834","journal-title":"Neurodegener Dis"},{"key":"1290_CR9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrd2896","volume":"9","author":"M Citron","year":"2010","unstructured":"Citron M (2010) Alzheimer\u2019s disease: strategies for disease modification. Nat Rev Drug Discov 9:387\u2013398. doi: 10.1038\/nrd2896","journal-title":"Nat Rev Drug Discov"},{"key":"1290_CR10","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","volume":"98","author":"RB DeMattos","year":"2001","unstructured":"DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-a beta antibody alters cns and plasma a beta clearance and decreases brain a beta burden in a mouse model of alzheimer\u2019s disease. Proc Natl Acad Sci USA 98:8850\u20138855. doi: 10.1073\/pnas.151261398","journal-title":"Proc Natl Acad Sci USA"},{"key":"1290_CR11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/nrd3842","volume":"11","author":"A Mullard","year":"2012","unstructured":"Mullard A (2012) Sting of alzheimer\u2019s failures offset by upcoming prevention trials. Nat Rev Drug Discov 11:657\u2013660. doi: 10.1038\/nrd3842","journal-title":"Nat Rev Drug Discov"},{"key":"1290_CR12","doi-asserted-by":"crossref","first-page":"9677","DOI":"10.1523\/JNEUROSCI.4742-11.2012","volume":"32","author":"O Adolfsson","year":"2012","unstructured":"Adolfsson O, Pihlgren M, Toni N et al (2012) An effector-reduced anti-\u03b2-amyloid (a\u03b2) antibody with unique a\u03b2 binding properties promotes neuroprotection and glial engulfment of a\u03b2. J Neurosci 32:9677\u20139689. doi: 10.1523\/jneurosci.4742-11.2012","journal-title":"J Neurosci"},{"issue":"Suppl 3","key":"1290_CR13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3233\/JAD-2011-0059","volume":"26","author":"EM Reiman","year":"2011","unstructured":"Reiman EM, Langbaum JB, Fleisher AS et al (2011) Alzheimer\u2019s prevention initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26(Suppl 3):321\u2013329. doi: 10.3233\/jad-2011-0059","journal-title":"J Alzheimers Dis"},{"key":"1290_CR14","unstructured":"World Health Organisation (2008) Proposed inn: List 100. WHO Drug Inform 22"},{"key":"1290_CR15","unstructured":"World Health Organisation (2011) Poposed inn: List 105. WHO Drug Inform 25"},{"key":"1290_CR16","unstructured":"Schroeter S, Games KD (2008) Prevention and treatment of cerebral amyloid angiopathy: Us 12\/106,206. US Patent Application"},{"key":"1290_CR17","unstructured":"Bales KR, Demattos R, Holtzman DM, Paul SM, Tsurushita N, Vasquez M (2001) Humanized antibodies that sequester amyloid beta peptide. US Patent Application"},{"key":"1290_CR18","unstructured":"Pfeifer A, Pihlgren M, Muhs AW, Ryan, Nicolau C, Greferath R (2008) Humanized antibodies to amyloid beta. US Patent Application"},{"key":"1290_CR19","author":"WM Kok","year":"2009","unstructured":"Kok WM, Scanlon DB, Karas JA et al (2009) Solid-phase synthesis of homodimeric peptides: Preparation of covalently-linked dimers of amyloid [small beta] peptide. Chem Commun. doi: 10.1039\/B912784D (6228-6230)","journal-title":"Chem Commun"},{"key":"1290_CR20","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00401-013-1083-z","volume":"125","author":"AD Watt","year":"2013","unstructured":"Watt AD, Perez KA, Rembach A et al (2013) Oligomers, fact or artefact? Sds-page induces dimerization of beta-amyloid in human brain samples. Acta Neuropathol 125:549\u2013564. doi: 10.1007\/s00401-013-1083-z","journal-title":"Acta Neuropathol"},{"key":"1290_CR21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1017\/S1041610209009405","volume":"21","author":"KA Ellis","year":"2009","unstructured":"Ellis KA, Bush AI, Darby D et al (2009) The australian imaging, biomarkers and lifestyle (aibl) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of alzheimer\u2019s disease. Int Psychogeriatr 21:672\u2013687. doi: 10.1017\/S1041610209009405","journal-title":"Int Psychogeriatr"},{"key":"1290_CR22","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1523\/JNEUROSCI.5180-09.2010","volume":"30","author":"VL Villemagne","year":"2010","unstructured":"Villemagne VL, Perez KA, Pike KE et al (2010) Blood borne amyloid-beta dimer correlates with clinical markers of alzheimer\u2019s disease. J Neurosci 30:6315\u20136322","journal-title":"J Neurosci"},{"key":"1290_CR23","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1021\/pr700859x","volume":"7","author":"T Koenig","year":"2008","unstructured":"Koenig T, Menze BH, Kirchner M et al (2008) Robust prediction of the mascot score for an improved quality assessment in mass spectrometric proteomics. J Proteome Res 7:3708\u20133717. doi: 10.1021\/pr700859x","journal-title":"J Proteome Res"},{"key":"1290_CR24","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1002\/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2","volume":"20","author":"DN Perkins","year":"1999","unstructured":"Perkins DN, Pappin DJC, Creasy DM, Cottrell JS (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:3551\u20133567. doi: 10.1002\/(SICI)1522-2683(19991201)20:18<3551:AID-ELPS3551>3.0.CO;2-2","journal-title":"Electrophoresis"},{"key":"1290_CR25","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1124\/jpet.104.081901","volume":"313","author":"KK Kandimalla","year":"2005","unstructured":"Kandimalla KK, Curran GL, Holasek SS, Gilles EJ, Wengenack TM, Poduslo JF (2005) Pharmacokinetic analysis of the blood-brain barrier transport of 125i-amyloid \u03b2 protein 40 in wild-type and alzheimer\u2019s disease transgenic mice (app, ps1) and its implications for amyloid plaque formation. J Pharmacol Exp Ther 313:1370\u20131378. doi: 10.1124\/jpet.104.081901","journal-title":"J Pharmacol Exp Ther"},{"key":"1290_CR26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer\u2019s disease. Lancet 368:387\u2013403","journal-title":"Lancet"},{"key":"1290_CR27","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(13)70044-9","volume":"12","author":"VL Villemagne","year":"2013","unstructured":"Villemagne VL, Burnham S, Bourgeat P et al (2013) Amyloid \u03b2 deposition, neurodegeneration, and cognitive decline in sporadic alzheimer\u2019s disease: a prospective cohort study. Lancet Neurol 12:357\u2013367. doi: 10.1016\/S1474-4422(13)70044-9","journal-title":"Lancet Neurol"},{"key":"1290_CR28","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/nm.2460","volume":"17","author":"DJ Selkoe","year":"2011","unstructured":"Selkoe DJ (2011) Resolving controversies on the path to alzheimer\u2019s therapeutics. Nat Med 17:1060\u20131065","journal-title":"Nat Med"},{"key":"1290_CR29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/scitranslmed.3002609","volume":"3","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Jack CR, Aisen PS (2011) Testing the right target and right drug at the right stage. Sci Transl Med 3:111\u2013133. doi: 10.1126\/scitranslmed.3002609","journal-title":"Sci Transl Med"},{"issue":"Suppl 1","key":"1290_CR30","first-page":"283","volume":"33","author":"AD Watt","year":"2013","unstructured":"Watt AD, Villemagne VL, Barnham KJ (2013) Metals, membranes, and amyloid-beta oligomers: key pieces in the alzheimer\u2019s disease puzzle? J Alzheimers Dis 33(Suppl 1):283\u2013293. doi: 10.3233\/jad-2012-129017","journal-title":"J Alzheimers Dis"},{"key":"1290_CR31","unstructured":"Pontecorvo M, Joshi A, Lu Met al. (2013) Relationship between solanezumab treatment and amyloid burden in mild to moderate ad patients. In: 7th Human Amyloid Imaging (HAI)"},{"key":"1290_CR32","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1038\/nm.2965","volume":"18","author":"J Vom Berg","year":"2012","unstructured":"Vom Berg J, Prokop S, Miller KR et al (2012) Inhibition of il-12\/il-23 signaling reduces alzheimer\u2019s disease-like pathology and cognitive decline. Nat Med 18:1812\u20131819. doi: 10.1038\/nm.2965","journal-title":"Nat Med"},{"key":"1290_CR33","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1110\/ps.073347208","volume":"17","author":"L Berglund","year":"2008","unstructured":"Berglund L, Andrade J, Odeberg J, Uhl\u00e9n M (2008) The epitope space of the human proteome. Protein Sci 17:606\u2013613. doi: 10.1110\/ps.073347208","journal-title":"Protein Sci"},{"key":"1290_CR34","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1006\/jmbi.1996.0284","volume":"258","author":"LL Bonnycastle","year":"1996","unstructured":"Bonnycastle LL, Mehroke JS, Rashed M, Gong X, Scott JK (1996) Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage. J Mol Biol 258:747\u2013762. doi: 10.1006\/jmbi.1996.0284","journal-title":"J Mol Biol"},{"key":"1290_CR35","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1126\/science.1079731","volume":"299","author":"LC James","year":"2003","unstructured":"James LC, Roversi P, Tawfik DS (2003) Antibody multispecificity mediated by conformational diversity. Science 299:1362\u20131367. doi: 10.1126\/science.1079731","journal-title":"Science"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-014-1290-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00401-014-1290-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-014-1290-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T02:59:46Z","timestamp":1565405986000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00401-014-1290-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["1290"],"URL":"https:\/\/doi.org\/10.1007\/s00401-014-1290-2","relation":{},"ISSN":["0001-6322","1432-0533"],"issn-type":[{"value":"0001-6322","type":"print"},{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,7]]}}}